Mood and psychotic disorders and type 2 diabetes: A metabolic triad

Canadian Journal of Diabetes

Volumn 29, Issue 2, 2005, Pages 122-132

  McIntyre, Roger S ^a,b   Mancini, Deborah A ^a   Pearce, Mark M ^b   Silverstone, Peter ^c   Chue, Pierre ^c   Misener, Virginia L ^d   Konarski, Jakub Z ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Antipsychotics; Bipolar disorder; Comorbidity; Lithium; Major depressive disorder; Mood stabilizers; Obesity; Overweight; Schizophrenia

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DULOXETINE; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; AKATHISIA; BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METABOLIC DISORDER; MOOD DISORDER; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 29144512041     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291:2581-2590.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press Inc; 1994.
3. Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49:124-138.
4. McIntyre RS, Konarski JZ. Bipolar disorder: a national health concern. CNS Spectr. 2004;9(11 suppl 12):6-15.
5. Meltzer HY. Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr. 2004;9(10 suppl 11):15-24.
6. Goldner EM, Hsu L, Waraich P, et al. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002;47:833-843.
7. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
8. American Dietetic Association. Position of the American Dietetic Association: integration of medical nutrition therapy and pharmacotherapy. J Am Diet Assoc. 2003;103:1363-1370.
9. Mathews CA, Reus VI. Genetic linkage in bipolar disorder. CNS Spectr. 2003;8:891-904.
10. Kendler KS. Hierarchy and heritability: the role of diagnosis and modeling in psychiatric genetics. Am J Psychiatry. 2002;159:515-518.
11. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40-68.
12. Verdoux H, Sutler AL. Perinatal risk factors for schizophrenia: diagnostic specificity and relationships with maternal psychopathology. Am J Med Genet. 2002;114:898-905.
13. Kendler KS. Twin studies of psychiatric illness: an update. Arch Gen Psychiatry. 2001;58:1005-1014.
14. Lesch KP. Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci. 2004;29:174-184.
15. Berto P, D'llario D, Ruffo P, et al. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ. 2000;3:3-10.
16. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60(suppl 1):4-6.
17. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000;45:21-28.
18. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850.
19. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181.
20. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903-912.
21. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498-502.
22. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol. 2004;19:369-386.
23. McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005. In press.
24. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-1520.
25. Dong M, Giles WH, Felitti VJ, et al. Insights into causal pathways for ischemic heart disease: adverse childhood experiences study. Circulation. 2004;110:1761-1766.
26. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does Cortisol play a role? Biol Psychiatry. 2004;55:1-9.
27. Tran PV, Bymaster FP, McNamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol. 2003;23:78-86.
28. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79-104.
29. Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs. 2004;18:505-520.
30. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18(suppl 2):5-17.
31. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
32. Hornquist JO, Wikby A, Stenstrom U, et al. Type II diabetes and quality of life: a review of the literature. Pharmacoeconomics. 1995;8(suppl 1):12-16.
33. Roberts RE, Kaplan GA, Shema SJ, et al. Are the obese at greater risk for depression? Am J Epidemiol. 2000;152:163-170.
34. Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care. 1993;16:1167-1178.
35. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069-1078.
36. Lustman PJ, Harper GW, Griffith LS, et al. Use of the Diagnostic Interview Schedule in patients with diabetes mellitus. J Nerv Ment Dis. 1986;174:743-746.
37. Williams JW Jr, Noel PH, Cordes JA, et al. Is this patient clinically depressed? JAMA. 2002;287:1160-1170.
38. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53-59.
39. Kooy FH. Hyperglycemia in mental disorders. Brain. 1919;42:214-289.
40. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-329.
41. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 2004;47:S67-S71.
42. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001;13:31-41.
43. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients [letter]. Lancet. 1989;1:495.
44. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27(suppl 2):S1-S1S2.
45. Keck PE, Buse JB, Dagogo-Jack S, et al. Managing Metabolic Concerns in Patients With Severe Mental Illness. Minneapolis, MN: Healthcare Information Programs, McGraw-Hill Healthcare Information Group; 2003:1-76.
46. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
47. Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: a review. Obes Rev. 2004;5:115-121.
48. McIntyre RS, Konarski JZ. Managing overweight/obesity and diabetes mellitus in schizophrenia. Curr Psychiatry. 2005;4:12-22.
49. McIntyre RS, Konarski JZ. Bipolar disorder, and disorders of glucose metabolism. Curr Psychiatry. 2005;4:11-18.
50. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):S28-S36.
51. Klett CJ, Caffey EM Jr. Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry. 1960;2:102-108.
52. Holden JMC, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics. 1970;11:551-561.
53. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
54. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US Seroquel Study Group. J Clin Psychopharmacol. 1996;16:158-169.
55. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96:265-273.
56. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-18.
57. Nair NP, Ahmed SK, Kin NM. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci. 1993;18:214-225.
58. Effexor® Product Monograph. In: Compendium of Pharmaceuticals and Specialties. Ottawa, ON: Canadian Pharmacists Association; 2005.
59. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-1056.
60. Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry. 2003;160:797.
61. Cooper AJ, Ashcroft G. Potentiation of insulin hypoglycaemia by MAOI antidepressant drugs. Lancet. 1966;1:407-409.
62. Parodi F. On the antidiabetic effect of phenelzine. Clin Ter. 1967;42:443-448.
63. van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia. 1965;8:67-78.
64. van Praag HM, Leijnse B. Some aspects of the metabolism of glucose and of the non-esterified fatty acids in depressive patients. Psychopharmacologia. 1966;9:220-233.
65. van Pragg H, Leijnse B. The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta. 1963;8:466-475.
66. Leak D, Dormandy TL. Possible relations of hypoglyccmia induced by mono-amine oxidase inhibition and angina pectoris. Proc Soc Exp Biol Med. 1961;108:597-600.
67. Wickstrom L, Pettersson K. Treatment of diabetics with monoamine-oxidase inhibitors. Lancet. 1964;13:995-997.
68. Cooper AJ, Keddie KM. Hypotensive collapse and hypoglycaemia after mebanazine - a monoamine-oxidase inhibitor. Lancet. 1964;13:1133-1134.
69. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med. 1997;59:241-250.
70. Muller-Oerlinghausen B, Passoth PM, Poser W, et al. Impaired glucose tolerance in long-term lithium-treated patients. Int Pharmacopsychiatry. 1979;14:350-362.
71. Mellerup ET, Dam H, Wildschiodtz G, et al. Diurnal variation of blood glucose during lithium treatment. J Affect Disord. 1983;5:341-347.
72. Jones GR, Lazarus JH, Davies CJ, et al. The effect of short term lithium carbonate in type II diabetes mellitus. Horm Metab Res. 1983;15:422-444.
73. Shah JH, DeLeon-Jones FA, Schickler R, et al. Symptomatic reactive hypoglycemia during glucose tolerance test in lithium-treated patients. Metabolism. 1986;35:634-639.
74. Demir E, Aysun S. Weight gain associated with valproate in childhood. Pediatr Neurol. 2000;22:361-364.
75. Stephen LJ, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001;42:1002-1006.
76. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172-177.
77. Jallon P, Picard F. Body weight gain and anticonvulsants: a comparative review. Drug Saf. 2001;24:969-978.
78. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to alproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
79. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63:1148-1155.
80. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017.
81. McIntyre RS, Mancini DA, McCann S, et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003;5:28-35.
82. Murray R. PCOS: Uncovering polycystic ovary syndrome. Diabetes Forecast. 2004;57(5):82-86.
83. Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism. 2002;51:1274-1278.
84. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol. 2002;249:835-841.
85. York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition. 2000;16:967-975.
86. MedWatch-Medical Product Safety Information. US Food and Drug Administration website. Available at: http://www. fda.gov/medwatch/SAFETY/2004/ oct04_quickview.htm. Accessed May 4, 2005.
87. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2004;27(suppl 1):S11-S14.
88. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157:179-184.
89. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161:608-620.
90. Bowman KM, Kasanin J. The sugar content of blood in emotional states. Arch Neurol Psychiat. 1929;21:342-362.
91. Whitehorn JC. The blood sugar in relation to emotional reactions. Am J Psychiatry. 1934;90:987-1005.
92. Raphael T, Parsons JP. Blood sugar studies in dementia praecox and other mental disorders. Arch Neurol Psychiat. 1921;5:681-709.
93. Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiat. 1922;8:184-196.
94. Kasanin J. The blood sugar curve in mental disease. II. The schizophrenic (dementia praecox) groups. Arch Neurol Psychiat. 1926;10:414-419.
95. McCowan PK, Quastel JH. Blood sugar studies in abnormal mental states. J Ment Sci. 1931;77:525-548.
96. Tod H. Studies on carbohydrate metabolism in nervous and mental disorders. I. Glucose tolerance tests in manic-depressive insanity and other depression. Edinburgh Med J. 1934;43:524-S27.
97. Diethelm O. Influence of emotions on dextrose tolerance. Arch Neurol Psychiat. 1936;36:342-360.
98. Tod H. Studies on carbohydrate metabolism in nervous and mental disorders. III. The disturbance of the glucose tolerance test caused by hypnotics in clinical doses. Edinburgh Med J. 1937;44:44-46.
99. Braceland JF, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry. 1946;102:108-110.
100. Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiat. 1946;56:74-78.
101. Dynes JB. Diabetes in schizophrenia and diabetes in non-psychotic medical patients. Dis Nerv Syst. 1969;30:341-344.
102. Tabata H, Kikuoka M, Kikuoka H, et al. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai. 1987;70(suppl 2):90-93.
103. Schwarz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry. 1968;125:253-255.
104. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978-982.
105. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry. 1980;21:270-275.
106. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia - a preliminary study. J Clin Hosp Pharm. 1986;11:297-299.
107. Eaton WW, Armenian H, Gallo J, et al. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19:1097-1102.
108. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68-73.
109. Kawakami N, Takatsuka N, Shimizu H, et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care. 1999;22:1071-1076.
110. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-1420.
111. Vestergaard P, Schou M. Does long-term lithium treatment induce diabetes mellitus? Neuropsychobiology. 1987;17:130-132.
112. Everson-Rose S, Meyer P, Pandey D, et al. Depression symptoms, insulin resistance, and diabetes risk in a multi-ethnic community sample of women. Psychosom Med. 2003;65:A10.
113. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.